9 November 2016
Personalised treatment could be an effective means of reducing the risk of cancer among people with diabetes.
New MedUni Vienna research has offered evidence that targeted precision medicine can help to address the established link between type 2 diabetes and cancer. This is an important development, as certain diabetes drugs are thought to exacerbate this risk.
Looking at data from around 300,000 Austrian type 2 diabetes patients treated with around 300 different combinations of diabetes drugs, it was shown that specific combinations could be used to reduce the risk of cancer.
Primary insulin-stimulating drugs, for example, displayed a significantly higher cancer risk than insulin inhibitors, especially in the case of pancreatic cancer in men and women, liver cancer in men and lymphoma in women.
However, if statins were taken at the same time, the risk was shown to be massively reduced, bringing the overall likelihood of cancer down to the same level as for non-diabetic patients.
Peter Klimek from the Section for Science of Complex Systems at MedUni Vienna said: "This shows that it is possible to optimise individual treatments to substantially reduce the general cancer risk for diabetes patients."
Posted by Edward Bartel
Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.